N1-(2,3-二氢-1H-茚-5-基)乙酰胺 | 59856-06-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: N1-(2,3-二氢-1H-茚-5-基)乙酰胺
• 英文名称: 5-acetamidoindane
• 英文别名: 5-Acetamidoindan；N-(2,3-dihydro-1H-inden-5-yl)acetamide
• CAS: 59856-06-3
• 化学式: C₁₁H₁₃NO
• mdl: MFCD00221464
• 分子量: 175.23
• InChiKey: WOYOJAPRKMBKEU-UHFFFAOYSA-N

物化性质

• 熔点：
  106 °C
• 沸点：
  213 °C(Press: 18 Torr)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H302,H335
• 储存条件：
  存储条件：室温、密封且干燥

反应信息

• 作为反应物：
  描述：

  N1-(2,3-二氢-1H-茚-5-基)乙酰胺 在 chromium(VI) oxide 、 盐酸 、 氢氧化钾 、 tetrafluoroboric acid 、 1,2-双(三甲基硅氧基)乙烷 、 溴 、 铜 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 50.5h， 生成 甲磺酰胺,N-[6-[(2,4-二氟苯基)硫代]-2,3-二氢-1-羰基-1H-茚-5-基]-
  参考文献：
  名称：

  Synthesis of 5-Methanesulfonamido-6-(2,4-Difluorophenylthio)-1-Indanone

  摘要：

  The ethylene ketal of 5-nitro-6-bromo-1-indanone 6 was prepared via oxidation of N-(6-Bromo-5-indanyl)-acetamide 1. A subsequent mild displace; merit and elaboration to 6-thiosubstituted-5amino indanone derivative 10 is also described.

  DOI：

  10.1080/00397919508011826
• 作为产物：
  描述：

  5-氨基茚旦 以85的产率得到N1-(2,3-二氢-1H-茚-5-基)乙酰胺
  参考文献：
  名称：

  5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2

  摘要：

  公开了化学式I的复合物及其药学上可接受的盐在治疗环氧化酶-2介导的疾病中的应用。

  公开号：

  US05604260A1

文献信息

• 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF
  申请人：Bennett Frank

  公开号：US20100322901A1

  公开（公告）日：2010-12-23

  The present invention relates to 5,6-ring annulated indole derivatives of the formula (I), compositions comprising at least one 5,6-ring annulated indole derivatives, and methods of using the 5,6-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

  本发明涉及公式（I）的5,6-环接合吲哚衍生物，包含至少一种5,6-环接合吲哚衍生物的组合物，以及利用这些5,6-环接合吲哚衍生物治疗或预防患者病毒感染或与病毒相关的疾病的方法。
• [EN] SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT SPIROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2016044770A1

  公开（公告）日：2016-03-24

  Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

  具有式（IX）的结构或其立体异构体、互变异构体或药学上可接受的盐的化合物，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、Q1----Q2、R6、R7、A、B、W、x和y如本文所定义，并提供。还提供了包括这些化合物的药物组合物和通过给予这些化合物治疗各种HAT相关疾病或疾病，包括癌症的方法。
• [EN] PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS<br/>[FR] DÉRIVÉS PYRAZOLO[1,5A]PYRIMIDINE UTILISÉS EN TANT QUE MODULATEURS DE IRAK4
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018234345A1

  公开（公告）日：2018-12-27

  Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

  本文描述了化合物的公式(I)、公式(II)、公式(III)、公式(IV)、公式(V)、公式(VI)、公式(VII)、公式(VIII)，以及这些化合物作为白细胞介素-1受体相关激酶(IRAK4)抑制剂的使用方法。
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL À POTASSIUM DE LA MEDULLA EXTERNE DU REIN
  申请人：MERCK SHARP & DOHME

  公开号：WO2013039802A1

  公开（公告）日：2013-03-21

  This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

  这项发明涉及具有结构式I的化合物及其药学上可接受的盐，这些化合物是肾外髓钾（ROMK）通道（Kir1.1）的抑制剂。式I的化合物可用作利尿剂和钠利尿剂，因此可用于治疗和预防由过多盐分和水分潴留引起的疾病，包括高血压和慢性和急性心力衰竭等心血管疾病。
• Imidazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04435406A1

  公开（公告）日：1984-03-06

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.